Solid Biosciences (SLDB)
(Delayed Data from NSDQ)
$7.85 USD
-0.79 (-9.14%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $7.85 0.00 (0.00%) 7:00 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
SLDB 7.85 -0.79(-9.14%)
Will SLDB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SLDB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SLDB
Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD
FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label
SLDB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Solid Biosciences (SLDB) Falls Despite FDA Rare Tag for DMD Drug
Beat the Market Like Zacks: Walmart, Novo Nordisk, Procter & Gamble in Focus
REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study
Other News for SLDB
REGENXBIO releases new data on DMD drug ahead of earnings
PepGen stock tumbles 25% following release of DMD drug data
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Solid Biosciences’ SGT-003: A Promising Leap in DMD Therapy with Cardiac Safety Superiority
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)